|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Evaluation of the updated definition of early allograft dysfunction in donation after brain death and donation after cardiac death liver allografts显示文摘BACKGROUND:An updated definition of early allograft dysfunction(EAD) was recently validated in a multicenter study of 300 deceased donor liver transplant recipients.This analysis did not differentiate between donation after brain death(DBD) and donation after cardiac death(DCD) allograft recipients.METHODS:We reviewed our prospectively entered database for all DBD(n=377) and DCD(n=38) liver transplantations between January 1,2006 and October 30,2011.The incidence of EAD as well as its ability to predict graft failure and survival was compared between DBD and DCD groups.RESULTS:EAD was a valid predictor of both graft and patient survival at six months in DBD allograft recipients,but in DCD allograft recipients there was no significant difference in the rate of graft failure in those with EAD(11.5%) compared with those without EAD(16.7%)(P=0.664) or in the rate of death in recipients with EAD(3.8%) compared with those without EAD(8.3%)(P=0.565).The graft failure rate in the first 6 months in those with international normalized ratio ≥1.6 on day 7 who received a DCD allograft was 37.5% compared with 6.7% for those with international normalized ratio <1.6 on day 7(P=0.022).CONCLUSIONS:The recently validated definition of EAD is a valid predictor of patient and graft survival in recipients of DBD allografts.On initial assessment,it does not appear to be a useful predictor of patient and graft survival in recipients of DCD allografts,however a study with a larger sample size of DCD allografts is needed to confirm these findings.The high ALT/AST levels in most recipients of DCD livers as well as the predisposition to biliary complications and early cholestasis make these parameters as poor predictors of graft failure.An alternative definition of EAD that gives greater weight to the INR on day 7 may be more relevant in this population. | Kris P Croome William Wall Douglas Quan Sai Vangala Vivian McAlister Paul Marotta Roberto Hernandez-Alejandro | 2012 | Hepatobiliary & Pancreatic Diseases International2012，11，4： | 15 |
| 2 | A comparison of survival and pathologic features of non-alcoholic steatohepatitis and hepatitis C virus patients with hepatocellular carcinoma显示文摘AIM:To compare the clinical outcome and pathologic features of non-alcoholic steatohepatitis(NASH) patients with hepatocellular carcinoma(HCC) and hepatitic C virus(HCV) patients with HCC(another group in which HCC is commonly seen) undergoing liver transplantation.METHODS:Patients transplanted for HCV and NASH at our institution from January 2000 to April 2011 were analyzed.All explanted liver histology and pre-transplant liver biopsies were examined by two specialist liver histopathologists.Patient demographics,disease free survival,explant liver characteristics and HCC features(tumour number,cumulative tumour size,vascular invasion and differentiation) were compared between HCV and NASH liver transplant recipients.RESULTS:A total of 102 patients with NASH and 283 patients with HCV were transplanted.The incidence of HCC in NASH transplant recipients was 16.7%(17/102).The incidence of HCC in HCV transplant recipients was 22.6%(64/283).Patients with NASH-HCC were statistically older than HCV-HCC patients(P < 0.001).A significantly higher proportion of HCV-HCC patients had vascular invasion(23.4% vs 6.4%,P = 0.002) and poorly differentiated HCC(4.7% vs 0%,P < 0.001) compared to the NASH-HCC group.A trend of poorer recurrence free survival at 5 years was seen in HCV-HCC patients compared to NASH-HCC who underwent a Liver transplantation(P = 0.11).CONCLUSION:Patients transplanted for NASH-HCC appear to have less aggressive tumour features compared to those with HCV-HCC,which likely in part accounts for their improved recurrence free survival. | Roberto Hernandez-Alejandro Kris P Croome Martin Drage Nathalie Sela Jeremy Parfitt Natasha Chandok Paul Marotta Cheryl Dale William Wall Douglas Quan | 2012 | World Journal of Gastroenterology2012，18，31： | 5 |
| 3 | American Society of Clinical Oncology Guideline for Antiemetics in Oncology: Update 2006显示文摘 | Kris MG Hesketh P J Somerfield MR | 2006 | Journal of Clinical Oncology2006，24，18： | 1 |
| 4 | Decreasing prevalence of β-lactamase production among respiratory tract isolates of Haemophilus influenzae in the United States显示文摘 | Kris P Cassie L | 2005 | Antimicrob Agents Chemother2005，49，6： | 1 |
| 5 | Dietary fatty acids, hemostasis, and cardiovascular disease risk 显示文摘 | LEFEVER M KRIS - ETJERTPM P M | 2004 | J Am Diet Assoc2004，104，： | 1 |
| 6 | Quality of life assessment in individuals with lung cancer:testing the Lung Cancer Symptom Scale (LESS) 显示文摘 | Hollen P J Gralla R J Kris M G | 1993 | European Journal of Cancer1993，29，： | 1 |
| 7 | American Society of Clinical Ontology guideline for antiemetics in oncology: update 2006显示文摘 | Kris MG Hesketh P J Somerfield MR | 2006 | J Clin Oncol2006，24，18： | 1 |
| 8 | Utility of a rapid B - type peptide assay in differentiating congestive heart failure from lung disease in patients presenting with dyspnea显示文摘 | Morrison LK Harrison A Kris hnaswamy P | 2002 | J Am Coll Cardiol2002，39，2： | 1 |
| 9 | Hyperglycemia: still an important predictor of adverse outcomes following AMI in the reperfusion era 显示文摘 | Vincent W Wong DR Kris P | 2004 | Diabetes Res Clin Practi2004，64，2： | 1 |
| 10 | High - monounsaturated fatty acid diets lower both plasma cholesterol and triacylglycerol concentrations 显示文摘 | KRIS - ETHERTON P M PEARSON T A WAN Y | 1999 | Am J Clin Nutr1999，70，6： | 1 |
| 11 | Functional interaction of β-catenin with the transcription factor LEF-1 显示文摘 | Behrens J von Kries J P Kunl M | 1996 | Nature1996，382，： | 1 |
| 12 | Hyperglycemia : Still an impor- tant predictor of adverse outcomes following AMI in the reperfu- sion era显示文摘 | Vincent W Wong DR Kris P | 2004 | Diabetes Res Clin Practi2004，64，2： | 1 |
| 13 | Lung cancer in US women: a contemporary epidemic 显示文摘 | PATEL J D BACH P B KRIS M G | 2004 | J Am Med Assoc2004，291，14： | 1 |
| 14 | Fish consumption,fish oil,omega-3 fatty acids,and cardiovascular disease显示文摘 | Kris Etherton P M Harris W S APPel L J | 2002 | Circulation2002，106，21： | 1 |
| 15 | Massive settlements of the Pacific oyster,Crassostrea gigas,in Scandinavia显示文摘 | Wrange A L Valero J Harkestad L S Strand O Lindegarth S Christensen H T Dolmer P Kri | | 0，，6： | 1 |
| 16 | Bioactive compounds in foods: their role in the prevention of cardiovascular disease and cancer显示文摘 | KRIS ETHERTON P M HECKER K D BONANOME A | 2002 | Am J Med2002，113，9： | 1 |
| 17 | Balance of unsaturated fatty acids is important to a cholesterol - lowering diet : comparison of mid - oleic sun- flower oil and olive oil on cardiovascular disease risk factors 显示文摘 | BINKOSK1 A E KRIS - ETHERTON P M WILSON T A | 2005 | J Am Diet Assoc2005，105，7： | 1 |
| 18 | Bioactive compounds in nutrition and health - research methodologies for establishing biological function: the antioxidant and anti - inflammatory effects of flavonoids on atherosclerosis 显示文摘 | Kris - Etherton P M Lefevre M Beecher G R | 2004 | Annu Rev Nutr2004，，51： | 1 |
| 19 | American society of clinical oncology guideline for Antiemetics in ontology: Update 2006 显示文摘 | Kris MG Hesketh P J Somerfield MR | 2006 | J Clin Oncol2006，24，18： | 1 |
| 20 | American Society of Clinical Oncology Guideline for Antiemetics in Oncology: Update 2006显示文摘 | Kris MG Hesketh P J Mark R | 2006 | J Clin Oncol2006，24，18： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员